{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:22:51Z","timestamp":1794601371464,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB\u2013D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant ICIs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009735), BRAF and MEK inhibitors (BRAF\/MEKis;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009119) or ICI plus any targeted therapy (ICI\u2009+\u2009TT;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009184) from 26 international sites in both trial (755, 72.7%) and nontrial (283, 27.3%) settings. ICI regimens included anti-programmed cell death protein 1 (PD-1) alone (PD-1 alone;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009242) and anti-PD-1 plus other immuno-oncology agent(s) (PD-1\u2009+\u2009IO;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009489). Outcomes included major pathological response (MPR), recurrence-free survival (RFS) and overall survival (OS). An MPR was achieved in 57.8% of patients with ICIs, 51.4% with BRAF\/MEKis and 44.6% with ICI\u2009+\u2009TT. PD-1\u2009+\u2009IO elicited higher MPR rates than PD-1 alone (61.4% versus 49.5%). The 5-year RFS rate was 61.0% with PD-1 alone, 73.9% with PD-1\u2009+\u2009IO, 37.4% with BRAF\/MEKis and 76.4% with ICI\u2009+\u2009TT; the 5-year OS rates were 83.3%, 87.5%, 69.8% and 83.9%, respectively. ICI-treated patients with MPR had 5-year OS rates of 98.8% with PD-1 alone and 97.9% with PD-1\u2009+\u2009IO and gained no benefit from continuing ICIs into the adjuvant setting. Neoadjuvant ICIs were active in\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant melanoma (MPR, 46.3%), acral melanoma (38.1%), in-transit metastases (66.7%) and oligometastases (41.2%), although subgroup sizes and relative effectiveness varied. Survival outcomes were excellent with neoadjuvant ICIs, particularly in patients achieving MPR, but poor with BRAF\/MEKis and mixed with ICI\u2009+\u2009TT. Predictive biomarker-driven trials, effective adjuvant strategies and subgroup-specific research are needed for nonresponders.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04677-z","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:03:20Z","timestamp":1790845400000},"page":"4136-4147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-8906","authenticated-orcid":false,"given":"In\u00eas","family":"Pires da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3309-6535","authenticated-orcid":false,"given":"Kristen A.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurriaan","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-5544","authenticated-orcid":false,"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-278X","authenticated-orcid":false,"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8692","authenticated-orcid":false,"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-3643","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-5737","authenticated-orcid":false,"given":"Milton","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8186-7284","authenticated-orcid":false,"given":"Tara C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-7030","authenticated-orcid":false,"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor V.","family":"Samoylenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-7290","authenticated-orcid":false,"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-773X","authenticated-orcid":false,"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7556-7608","authenticated-orcid":false,"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-4655","authenticated-orcid":false,"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Trojaniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5313","authenticated-orcid":false,"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4219","authenticated-orcid":false,"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Hammoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Benannoune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-3611","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-295X","authenticated-orcid":false,"given":"Cigdem","family":"Dinckal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1746-2549","authenticated-orcid":false,"given":"Angelina","family":"Kuzmenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-4104","authenticated-orcid":false,"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-9050","authenticated-orcid":false,"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":false,"given":"Michael A.","family":"Postow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6426","authenticated-orcid":false,"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A. M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-5430","authenticated-orcid":false,"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"da Meda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Burnette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czarnekca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-2206","authenticated-orcid":false,"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-7892","authenticated-orcid":false,"given":"Geke","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lochrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C. J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-4922","authenticated-orcid":false,"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A. van de","family":"Wiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-5846","authenticated-orcid":false,"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"4677_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","volume":"372","author":"AM Eggermont","year":"2008","unstructured":"Eggermont, A. M. et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117\u2013126 (2008).","journal-title":"Lancet"},{"key":"4677_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522\u2013530 (2015).","journal-title":"Lancet Oncol."},{"key":"4677_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR8","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","volume":"26","author":"JM Versluis","year":"2020","unstructured":"Versluis, J. M., Long, G. V. & Blank, C. U. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 26, 475\u2013484 (2020).","journal-title":"Nat. Med."},{"key":"4677_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ccell.2024.05.015","volume":"42","author":"R Saddawi-Konefka","year":"2024","unstructured":"Saddawi-Konefka, R., Schokrpur, S. & Gutkind, J. S. Let it be: preserving tumor-draining lymph nodes in the era of immuno-oncology. Cancer Cell 42, 930\u2013933 (2024).","journal-title":"Cancer Cell"},{"key":"4677_CR11","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382\u20131399 (2016).","journal-title":"Cancer Discov."},{"key":"4677_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 (2017).","journal-title":"Cancer Cell"},{"key":"4677_CR13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel, S. P. et al. Neoadjuvant\u2013adjuvant or adjuvant only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813\u2013823 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR15","doi-asserted-by":"publisher","first-page":"S1600","DOI":"10.1016\/j.annonc.2025.09.069","volume":"36","author":"MW Lucas","year":"2025","unstructured":"Lucas, M. W. et al. LBA57 two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma. Ann. Oncol. 36, S1600\u2013S1601 (2025).","journal-title":"Ann. Oncol."},{"key":"4677_CR16","first-page":"S882","volume":"36","author":"SP Patel","year":"2025","unstructured":"Patel, S. P. et al. 1601O 3-year survival with neoadjuvant\u2013adjuvant pembrolizumab from SWOG S1801. Ann. Oncol. 36, S882\u2013S883 (2025).","journal-title":"Ann. Oncol."},{"key":"4677_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655\u20131661 (2018).","journal-title":"Nat. Med."},{"key":"4677_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral, T. et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up. Ann. Oncol. 36, 10\u201330 (2025).","journal-title":"Ann. Oncol."},{"key":"4677_CR19","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Melanoma Cutaneous v1.2026 (National Comprehensive Cancer Network (NCCN), 2026)."},{"key":"4677_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41591-023-02336-1","volume":"29","author":"C Garbe","year":"2023","unstructured":"Garbe, C. et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat. Med. 29, 1310\u20131312 (2023).","journal-title":"Nat. Med."},{"key":"4677_CR21","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1200\/JCO.22.02575","volume":"41","author":"GV Long","year":"2023","unstructured":"Long, G. V., Menzies, A. M. & Scolyer, R. A. Neoadjuvant checkpoint immunotherapy and melanoma: the time is now. J Clin. Oncol. 41, 3236\u20133248 (2023).","journal-title":"J Clin. Oncol."},{"key":"4677_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181\u2013193 (2018).","journal-title":"Lancet Oncol."},{"key":"4677_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 20, 961\u2013971 (2019).","journal-title":"Lancet Oncol."},{"key":"4677_CR24","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"4677_CR25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"4677_CR26","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN\u2013neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948\u2013960 (2019).","journal-title":"Lancet Oncol."},{"key":"4677_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301\u2013309 (2021).","journal-title":"Nat. Med."},{"key":"4677_CR28","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff, M. T. et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann. Oncol. 29, 1861\u20131868 (2018).","journal-title":"Ann. Oncol."},{"key":"4677_CR29","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin. Cancer Res. 29, 3352\u20133361 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4677_CR30","doi-asserted-by":"publisher","first-page":"EVIDoa2200214","DOI":"10.1056\/EVIDoa2200214","volume":"1","author":"AMM Eggermont","year":"2022","unstructured":"Eggermont, A. M. M. et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 1, EVIDoa2200214 (2022).","journal-title":"NEJM Evid."},{"key":"4677_CR31","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","volume":"391","author":"GV Long","year":"2024","unstructured":"Long, G. V. et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N. Engl. J. Med. 391, 1709\u20131720 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4677_CR32","doi-asserted-by":"publisher","first-page":"9579","DOI":"10.1200\/JCO.2024.42.16_suppl.9579","volume":"42","author":"IED Pires da Silva","year":"2024","unstructured":"Pires da Silva, I. E. D. et al. Neoadjuvant immunotherapy (neoIT) in melanoma: a prediction tool for pathological response and recurrence, and the role of adjuvant (Adj) therapy (Tx) to improve recurrence-free survival (RFS). J. Clin. Oncol. 42, 9579 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4677_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria, R. N. et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611, 155\u2013160 (2022).","journal-title":"Nature"},{"key":"4677_CR34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat. Med. 28, 1178\u20131188 (2022).","journal-title":"Nat. Med."},{"key":"4677_CR35","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1200\/JCO-25-00494","volume":"43","author":"EM Burton","year":"2025","unstructured":"Burton, E. M. et al. Long-term survival and biomarker analysis evaluating neoadjuvant plus adjuvant relatlimab (anti-LAG3) and nivolumab (anti-PD1) in patients with resectable melanoma. J. Clin. Oncol. 43, 2856\u20132862 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4677_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","volume":"31","author":"R Dummer","year":"2025","unstructured":"Dummer, R. et al. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB\u2013D melanoma: a phase 1\/2 trial. Nat. Med. 31, 144\u2013151 (2025).","journal-title":"Nat. Med."},{"key":"4677_CR37","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","volume":"31","author":"GV Long","year":"2025","unstructured":"Long, G. V. et al. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus\u2013Melanoma trial. Nat. Med. 31, 3700\u20133712 (2025).","journal-title":"Nat. Med."},{"key":"4677_CR38","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber, J. S. et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB\u2013D or stage IV melanoma (CheckMate 915). J. Clin. Oncol. 41, 517\u2013527 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4677_CR39","doi-asserted-by":"publisher","first-page":"e012034","DOI":"10.1136\/jitc-2025-012034","volume":"13","author":"GV Long","year":"2025","unstructured":"Long, G. V. et al. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB\u2013D\/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. J. Immunother. Cancer 13, e012034 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"4677_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","volume":"157","author":"ILM Reijers","year":"2022","unstructured":"Reijers, I. L. M. et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg. 157, 335\u2013342 (2022).","journal-title":"JAMA Surg."},{"key":"4677_CR41","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1245\/s10434-021-11236-y","volume":"29","author":"ACJ van Akkooi","year":"2022","unstructured":"van Akkooi, A. C. J. et al. Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann. Surg. Oncol. 29, 3694\u20133708 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"4677_CR42","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41591-025-04158-9","volume":"32","author":"LL Hoeijmakers","year":"2026","unstructured":"Hoeijmakers, L. L. et al. Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO trial. Nat. Med. 32, 952\u2013963 (2026).","journal-title":"Nat. Med."},{"key":"4677_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-024-03153-1","volume":"43","author":"WY Chan","year":"2024","unstructured":"Chan, W. Y. et al. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy. J. Exp. Clin. Cancer Res. 43, 238 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"4677_CR44","doi-asserted-by":"publisher","first-page":"e011483","DOI":"10.1136\/jitc-2025-011483","volume":"13","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J. Immunother. Cancer 13, e011483 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"4677_CR45","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.annonc.2025.08.551","volume":"36","author":"I Pires da Silva","year":"2025","unstructured":"Pires da Silva, I. et al. 117MO clinical and multi-omics predictive model of resistance to neoadjuvant anti-PD1 (PD1) in melanoma. Ann. Oncol. 36, S241 (2025).","journal-title":"Ann. Oncol."},{"key":"4677_CR46","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert, C. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668\u20131674 (2018).","journal-title":"J. Clin. Oncol."},{"key":"4677_CR47","doi-asserted-by":"publisher","first-page":"906251","DOI":"10.3389\/fonc.2022.906251","volume":"12","author":"M Jiang","year":"2022","unstructured":"Jiang, M., Hu, Y., Lin, G. & Chen, C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front. Oncol. 12, 906251 (2022).","journal-title":"Front. Oncol."},{"key":"4677_CR48","doi-asserted-by":"publisher","first-page":"113563","DOI":"10.1016\/j.ejca.2024.113563","volume":"199","author":"SK Jacques","year":"2024","unstructured":"Jacques, S. K. et al. Outcomes of patients with resected stage III\/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur. J. Cancer 199, 113563 (2024).","journal-title":"Eur. J. Cancer"},{"key":"4677_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"4677_CR50","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young, H. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur. J. Cancer 35, 1773\u20131782 (1999).","journal-title":"Eur. J. Cancer"},{"key":"4677_CR51","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"20","author":"RN Amaria","year":"2019","unstructured":"Amaria, R. N. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 20, e378\u2013e389 (2019).","journal-title":"Lancet Oncol."},{"key":"4677_CR52","doi-asserted-by":"publisher","unstructured":"R Core Team R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2026); https:\/\/doi.org\/10.32614\/R.manuals","DOI":"10.32614\/R.manuals"},{"key":"4677_CR53","unstructured":"Posit Team RStudio: Integrated Development Environment for R Posit Software (PBC, 2026); http:\/\/www.posit.co\/"},{"key":"4677_CR54","unstructured":"Wickham, H., Fran\u00e7ois, R., Henry, L., M\u00fcller, K. & Vaughan, D. dplyr: A grammar of data manipulation. R version 1.2.1 https:\/\/CRAN.R-project.org\/package=dplyr (2026)."},{"key":"4677_CR55","unstructured":"Wickham, H., Vaughan, D. & Girlich, M. tidyr: Tidy messy data. R version 1.3.2 https:\/\/CRAN.R-project.org\/package=tidyr (2025)."},{"key":"4677_CR56","unstructured":"Wickham, H. stringr: Simple, consistent wrappers for common string operations. R version 6.0 https:\/\/CRAN.R-project.org\/package=stringr (2025)."},{"key":"4677_CR57","unstructured":"Wickham, H. forcats: Tools for working with categorical variables (factors). R version v1.0.1 https:\/\/CRAN.R-project.org\/package=forcats (2025)."},{"key":"4677_CR58","unstructured":"Therneau, T. M. survival: A package for survival analysis in R. R version 3.8-9 https:\/\/CRAN.R-project.org\/package=survival (2026)."},{"key":"4677_CR59","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche, P., Dartigues, J. F. & Jacqmin-Gadda, H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat. Med. 32, 5381\u20135397 (2013).","journal-title":"Stat. Med."},{"key":"4677_CR60","unstructured":"Rich, B. table1: Tables of descriptive statistics in HTML. R version 5.1 https:\/\/CRAN.R-project.org\/package=table1 (2025)."},{"key":"4677_CR61","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer\u2013Verlag, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"4677_CR62","unstructured":"Kassambara, A., Kosinski, M. & Biecek, P. survminer: Drawing survival curves using \u2018ggplot2\u2019. R version 0.5.2 https:\/\/CRAN.R-project.org\/package=survminer (2026)."},{"key":"4677_CR63","unstructured":"Slowikowski, K. ggrepel: Automatically position non-overlapping text labels with \u2018ggplot2\u2019. R version 0.9.8 https:\/\/CRAN.R-project.org\/package=ggrepel (2026)."},{"key":"4677_CR64","unstructured":"Wilke, C. & Wiernik, B. ggtext: Improved text rendering support for \u2018ggplot2\u2019. R version 0.1.2 https:\/\/CRAN.R-project.org\/package=ggtext (2022)."},{"key":"4677_CR65","unstructured":"Brunson, J. C. & Read, Q. D. ggalluvial: Alluvial plots in \u2018ggplot2\u2019. R version 0.12.6 http:\/\/corybrunson.github.io\/ggalluvial\/ (2026)."},{"key":"4677_CR66","unstructured":"Rinker, T. W. & Kurkiewicz, D. pacman: Package management for R. R version 0.5.1 http:\/\/github.com\/trinker\/pacman (2017)."},{"key":"4677_CR67","unstructured":"SAS v9.4 (SAS Institute, 2013)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04677-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:49:32Z","timestamp":1794599372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04677-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4677"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04677-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.V.L. is a consultant or advisor for Boehringer Ingelheim, Byondis B.V., Evaxion A\/S, Fortiva Biologics, G.I. Innovation, Immunocore Ireland, Innovent Biologics (Suzhou), Iovance Biotherapeutics, Regeneron Pharmaceuticals, Replimmune, Scancell and Strand Therapeutics. I.P.d.S. is a consultant or advisor for Merck Sharp & Dohme, Regeneron and Strand, and has received speaker fees from Roche, Pierre Fabre and QBiotics. P.G. is a consultant or advisor for Bristol Myers Squibb and Ipsen, and has received conference attendance support from BeOne, Bristol Myers Squibb, Ipsen, Merck Sharp & Dohme, Pierre Fabre and Servier. R.N.A. is a consultant or advisor for Erasca, Immatics, KSQ Therapeutics, IOBiotech and Obsidian. S.S. is a consultant or advisor for AbbVie, AdvanCell, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Erasca, Janssen, Macrogenics, Merck Sharp & Dohme, Novartis and Skyline Diagnostics, with all honoraria paid to the institute; has received research grants from Amgen, AstraZeneca, Endocyte (a Novartis company), Merck Healthcare, Merck Sharp & Dohme, Pfizer, Roche\/Genentech and Senhwa Biosciences, all paid to the institute; and owns stock in AdvanCell. D.B.J. is a consultant or advisor for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Jackson Laboratories, Merck, Pfizer and Therakos. P.R. has received honoraria for lectures and advisory boards from Bristol Myers Squibb, Genesis Pharma, Medison Pharma, Merck Sharp & Dohme and Pierre Fabre, and is a consultant or advisor for Erasca. M.S.B. reports institutional research support from Alkermes, Bristol Myers Squibb, Genentech, Merck, nFerence, Perspective Therapeutics, Pharmacyclics, Regeneron, Sorrento, TILT Biotherapeutics and Transgene. E.M.-C. is a consultant or advisor for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi and Regeneron; has received research funding from Bristol Myers Squibb, Merck Sharp & Dohme and Sanofi; has received speaker fees from Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre and Regeneron; and was principal investigator for trials sponsored by Amgen, Bristol Myers Squibb, GlaxoSmithKline, Iovance, Merck Sharp & Dohme, Novartis, Pierre Fabre, Regeneron, Roche and Sanofi. M.S.C. is a consultant or advisor for Amgen, Bristol Myers Squibb, Eisai, Ideaya, Merck Sharp & Dohme, Nektar, Novartis, Oncosec, Pierre Fabre, Qbiotics, Regeneron, Roche, Merck, Moderna and Sanofi, and received honoraria from Bristol Myers Squibb, Merck Sharp & Dohme and Novartis. M.J. is a consultant or advisor for Regeneron and Bristol Myers Squibb, with fees paid to the institute. M.A.P. is a consultant or advisor for Bristol Myers Squibb, Chugai, Erasca, Eisai, Lyvgen, Merck, Nektar, Novartis, Pfizer and Replimune, and has received institutional support from BioAtla, Bristol Myers Squibb, Genentech, Infinity, Merck, Novartis and RGenix. E.K. is a consultant or advisor for Bristol Myers Squibb, Delcath and Immunocore, and has received research grants from Bristol Myers Squibb, Delcath, Novartis and Pierre Fabre, all paid to the institute. A.A.M.v.d.V. is a consultant or advisor for Bristol Myers Squibb, Dutch Melanoma Guideline, GE Health Care, Ipsen, Merck Sharp & Dohme, Novartis, Regeneron, Pierre Fabre and Sanofi, with fees paid to the institute. K.P.M.S. is a consultant or advisor for Abbvie and Sairopa; has received honoraria from Bristol Myers Squibb and Novartis; and has received research funding from Bristol Myers Squibb, Genmab, Philips and Pierre Fabre, all paid to the institute. A.C.J.v.A. is a consultant or advisor for Adium, Amgen, Bristol Myers Squibb, Daiichi Sankyo, Genmab, Menarini Silicon Biosystems, Merck Serono\u2013Pfizer, MSD, Neracare, Novartis, Pierre Fabre, Provectus, Regeneron, Replimune, Sanofi, Sirius Medical, SkylineDx and 4SC; and has received research funding from Amgen, Merck Serono\u2013Pfizer and SkylineDx. M.T.T. has advisory board relationships with Merck, Moderna, Regeneron and Replimmune; has performed central pathology review for Merck (with funds paid to the University of California San Francisco) and Philogen (pending); and has received educational honoraria from Clinical Care Options\/Scientific Satellite Symposium at the American Association for Cancer Research (AACR) Annual Meeting, from Merck and Elsevier (textbook royalties). C.U.B. is a consultant or advisor with Bristol Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures and Senya; has received research funding from Bristol Myers Squibb, Novartis, NanoString and 4SC; and is co-founder of Immagene, all paid to the institution, except for Third Rock Ventures and Immagene. A.M.M. is a consultant or advisor for Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Pierre Fabre and QBiotics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}